UBS Group AG Raises Position in Organon & Co. $OGN

UBS Group AG grew its holdings in shares of Organon & Co. (NYSE:OGN) by 55.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,295,002 shares of the company’s stock after purchasing an additional 1,527,492 shares during the quarter. UBS Group AG’s holdings in Organon & Co. were worth $30,795,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in OGN. Vanguard Group Inc. lifted its stake in shares of Organon & Co. by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after purchasing an additional 3,650,860 shares during the period. AQR Capital Management LLC lifted its stake in shares of Organon & Co. by 136.1% during the 2nd quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company’s stock worth $31,507,000 after purchasing an additional 1,876,264 shares during the period. Balyasny Asset Management L.P. lifted its stake in shares of Organon & Co. by 102.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock worth $23,925,000 after purchasing an additional 1,131,941 shares during the period. Gotham Asset Management LLC lifted its stake in shares of Organon & Co. by 37.2% during the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock worth $39,657,000 after purchasing an additional 1,007,691 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after purchasing an additional 801,307 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Up 0.2%

Shares of NYSE OGN opened at $13.35 on Friday. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.44. The company has a market cap of $3.50 billion, a P/E ratio of 14.35, a P/E/G ratio of 1.24 and a beta of 1.57. The company has a current ratio of 1.97, a quick ratio of 1.23 and a debt-to-equity ratio of 9.47. The stock has a fifty day moving average price of $8.00 and a 200 day moving average price of $7.82.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the company posted $1.02 earnings per share. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. Research analysts anticipate that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Monday, May 11th will be issued a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, May 11th. Organon & Co.’s dividend payout ratio is currently 8.60%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Wall Street Zen lowered Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Barclays increased their price target on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 24th. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Finally, Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and increased their price target for the stock from $5.00 to $14.00 in a research note on Tuesday, April 28th. Four investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $11.40.

Insider Transactions at Organon & Co.

In related news, SVP Lynette Holzbaur purchased 26,448 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was purchased at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.62% of the company’s stock.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.